文献速递消化道肿瘤与早癌

未选择结直肠腺癌患者中的胚系癌症易感基因检测:多中心前瞻性研究

Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-04-20

BACKGROUND & AIMS: Hereditary factors play a role in the development of colorectal cancer (CRC). Identification of germline predisposition can have implications on treatment and cancer prevention.…

要点

  • 未选择结直肠癌患者中致病性胚系变异检出率为15.5%。
  • 9.4%患者有指南标准或结直肠癌专属panel未覆盖的可操作发现。
  • 仅年轻年龄与致病性胚系变异相关(OR 1.99, 95%CI 1.12-3.56)。

核心结论

  • 在未选择的结直肠癌患者中,通用多基因panel检测较指南标准检测可额外发现少量但有意义的遗传性突变。
  • 约十分之一患者的管理因检测结果发生改变,但家族级联检测接受率低。

研究设计与样本

  • 前瞻性多中心研究,2018年4月1日至2020年3月31日在Mayo Clinic癌症中心纳入361例未按年龄或家族史选择的结直肠癌患者。
  • 采用80余基因下一代测序平台进行胚系测序。

主要发现

  • 361例患者中位年龄57岁(SD 12.4),43.5%女性,82%白人,38.2%为IV期。
  • 15.5%(n=56)检出致病性胚系变异,其中44例位于中高外显率癌症易感基因。
  • 仅诊断时年轻年龄与致病性胚系变异相关(OR 1.99, 95%CI 1.12-3.56)。

关键数值与推荐

  • 家族级联检测接受率为16%。

临床怎么用

  • 对未选择的结直肠癌患者可考虑通用多基因胚系检测以发现指南标准可能遗漏的可操作变异。
  • 检测结果可能影响治疗决策,但需关注并提高家族级联检测的接受率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hereditary factors play a role in the development of colorectal cancer (CRC). Identification of germline predisposition can have implications on treatment and cancer prevention. This study aimed to determine the prevalence of pathogenic germline variants (PGVs) in CRC patients using a universal testing approach, association with clinical outcomes, and the uptake of family variant testing. METHODS: We performed a prospective multisite study of germline sequencing using a more than 80-gene next-generation sequencing platform among CRC patients (not selected for age or family history) receiving care at Mayo Clinic Cancer Centers between April 1, 2018, and March 31, 2020. RESULTS: Of 361 patients, the median age was 57 years (SD, 12.4 y), 43.5% were female, 82% were white, and 38.2% had stage IV disease. PGVs were found in 15.5% (n = 56) of patients, including 44 in moderate- and high-penetrance cancer susceptibility genes. Thirty-four (9.4%) patients had incremental clinically actionable findings that would not have been detected by practice guideline criteria or a CRC-specific gene panel. Only younger age at diagnosis was associated with the presence of PGVs (odds ratio, 1.99; 95% CI, 1.12-3.56). After a median follow-up period of 20.7 months, no differences in overall survival were seen between those with or without a PGV (P = .2). Eleven percent of patients had modifications in their treatment based on genetic findings. Family cascade testing was low (16%). CONCLUSIONS: Universal multigene panel testing in CRC was associated with a modest, but significant, detection of heritable mutations over guideline-based testing. One in 10 patients had changes in their management based on test results. Uptake of cascade family testing was low, which is a concerning observation that warrants further study.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Uson PLS, Riegert-Johnson D, Boardman L, et al. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. Clin Gastroenterol Hepatol. 2021. PMID: 33857637. doi:10.1016/j.cgh.2021.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。